MoonLake Immunotherapeutics (MLTX) — Capital Reinvestment Ratio
Latest as of June 2021:
2.61x
MoonLake Immunotherapeutics (MLTX) has a Capital Reinvestment Ratio of 2.61x as of June 2021, meaning it reinvests 3% of its operating cash flow ($6.14K) in capital expenditures ($16.01K). See MLTX equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
2.61x
Capex / Operating Cash Flow
Operating Cash Flow
$6.14K
USD
Capital Expenditures
$16.01K
USD
Data as of
Jun 2021
Most recent filing
Annual Capital Reinvestment Ratio for MoonLake Immunotherapeutics (None–None)
Year-by-year Capital Reinvestment Ratio for MoonLake Immunotherapeutics from None to None. For live market cap and broader valuation context, see market cap of MoonLake Immunotherapeutics.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow